Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Int J Oncol. Author manuscript; available in PMC 2009 March 1.
Published in final edited form as:
PMCID: PMC2267753

Downregulation of Matrix Metalloproteinase-2 (MMP-2) Utilizing Adenovirus-mediated Transfer of Small Interfering RNA (siRNA) in a Novel Spinal Metastatic Melanoma Model


Matrix metalloproteinases (MMPs) comprise a class of secreted zinc-dependent endopeptidases implicated in the metastatic potential of tumor cells due to their ability to degrade the extracellular matrix (ECM) and basement membrane. Matrix metalloproteinase-2 (MMP-2) has been detected in high levels and correlates with invasiveness in human melanoma. We have studied the effect of adenovirus-mediated transfer of small interfering RNA (siRNA) against MMP-2 in the human melanoma cell line A2058. The delivery of these double-stranded RNA molecules represents an efficient technology in silencing disease-causing genes with known sequences at the post-transcriptional level. siRNA against MMP-2 mRNA (Ad-MMP-2) was found to decrease MMP-2 protein expression and activity in melanoma cells as demonstrated by western blotting and gelatin zymography. Furthermore, infection of cells with Ad-MMP-2 inhibited cellular migration and invasion as indicated by spheroid and matrigel assays. We also observed dose-dependent suppression of vascular network formation in an angiogenesis assay. Finally, we developed a nude mouse spinal metastatic model to investigate the local effects of tumor metastasis. Intravenous tail vein injection with Ad-MMP-2 on days 5, 9, and 11 resulted in complete retention of neurological function as compared to control and scrambled vector (Ad-SV)-treated groups that showed complete paraplegia by day 14 ± 2 days. Hematoxylin and eosin staining revealed decreased tumor size in the Ad-MMP-2-treated animals. This novel experimental model revealed that adenoviral-mediated transfer of RNA interference against MMP-2 results in the retention of neurological function and significantly inhibited tumor growth.

Keywords: MMP-2, melanoma, invasion, spheroid migration, angiogenesis, metastatic model


Although cutaneous melanoma represents only 1% of all cancers and accounts for approximately 50,000 new cases per year, this melanoma has one of the most rapidly increasing incidences of all solid tumors (1,2). It is one of the most common and aggressive cancers, occurring in the third decade of life and often presenting with extensive skeletal metastasis at the time of diagnosis (3,4). Although vertebral metastasis causes a diminished quality of life as a result of pain and paraplegia, treatment options remain undefined and ineffective (5). Complicating matters further is the fact that melanoma is a radioresistant tumor, leaving even less options available to the treating physician (6). Thus, effective pharmacologic alternatives to halt the progression of disease are needed to augment the insufficient medical and surgical armamentarium, as it currently exists.

As a lesion originating within the epidermis, malignant melanomas possess unique characteristics for efficient dissemination throughout the body. Among these is the group of zinc-dependent endopeptidases termed matrix metalloproteinases (MMPs). These enzymes have wide-ranging roles in non-pathological and pathological states as they are involved in a variety of tissue remodeling processes including wound healing, cellular migration, invasion and angiogenesis (7-9). More than 20 molecules belong to this family and are subdivided into collagenases, gelatinases, stromelysins, matrilysins, and membrane-type MMPs. In vitro data has specifically implicated the 72-kD gelatinase MMP-2 in the pivotal role of melanoma invasion. MMP-2 is secreted as a latent pro-form and processed into an active enzyme through cell surface interactions with specific tissue inhibitors (TIMPs) (10). Of all the MMPs and TIMPs assayed in a human melanoma xenograft model, only the expression of activated MMP-2 correlated with the aggressive malignant phenotype (11). Other studies have duplicated this observation in other models (12-15). Clinical aspects of MMP-2 expression have been validated in human biopsy specimens where a 70.5% negative rate of immunohistochemical expression was found in patients with good prognosis compared with only a 47% negative rate in those who developed metastasis (16). Serum levels of MMP-2 have also been found to be elevated in those with metastasizing melanoma compared to those with unifocal disease. However, at this point, the clinical application of this information remains undefined (16,17).

In the present study, we have used RNA interference (RNAi) to downregulate the expression of MMP-2. RNAi, and more specifically, small interfering RNA (siRNA), has emerged as a potent tool in post-transcriptional regulation due to its inherent specificity for known gene sequences and its versatility against many pathogens as diverse siRNAs can be designed (18). In the present study, we utilized an adenovirus-mediated method of transferring siRNA as recent studies have shown this method to be a more efficient delivery mechanism (19,20). Our results confirm that adenovirus-mediated transfer of siRNA against MMP-2 resulted in downregulation with subsequent decreases in invasion, migration and angiogenesis. Furthermore, for the first time, we describe a novel metastatic spine model in nude mice in which we validate these results via 100% retention of neurological function and decreased tumor growth as compared to control animals.


Cell cultures and adenoviral constructs

The human melanoma cell line A2058 was grown in Dulbecco’s modified Eagle’s medium (DMEM). Cultures were supplemented with 1% glutamine, 100 μg/mL streptomycin, 100 U/mL penicillin, and 10% fetal bovine serum (pH 7.2 to 7.4) and maintained in a humidified atmosphere containing 5% CO2 at 37°C. The adenoviral constructs carrying siRNA against MMP-2 (Ad-MMP-2) and a scrambled MMP-2 sequence (Ad-SV) were designed and constructed as described previously (20). Briefly, the following siRNA sequences were cloned into the pSuppressor vector:


We used the adenoviral pSuppressor kit (Imgenex, San Diego, CA) to create the final constructs as per the manufacturer’s instructions. The pSuppressor plasmids were digested with PacI and co-transfected with pAd vector backbone in 293 cells for recombinant generation of the adenoviruses carrying MMP-2 siRNA and the scrambled sequence. Viruses were plaque purified and used to infect 293 cells, and subsequently purified on a cesium chloride gradient and tittered as previously described (20). The amount of infective adenoviral vector per cell (pfu/cell) in culture media was expressed as multiplicity of infection (MOI). Virus constructs were diluted in serum-free culture media to the desired concentration and added to cells and incubated at 37°C for 1 h. The necessary amount of complete medium was then added and cells were incubated for the desired time periods.

Gelatin zymography

Cells were infected with mock, Ad-SV (100 MOI) or Ad-MMP-2 (12.5, 25, 50 and 100 MOI). Twenty-four hours after infection, conditioned medium was replaced with serum-free medium, and cells were incubated overnight. Thirty micrograms of each sample were assayed for gelatinase activity as described previously (20). Briefly, electrophoresis was performed on 10% SDS-PAGE containing 1 mg/mL gelatin. Gels were washed in 2.5% Triton X-100 and incubated overnight at 37°C in a buffer (50 mmol/L Tris-HCl, 0.05% NaN3, 5mmol/L CaCl2 and 1 μmol/L ZnCl2, pH 7.6). Gels were stained with Amido black solution, destained and MMP-2 activity was visualized as clear bands on a dark background.

Western blot analysis

A2058 cells were mock infected or infected with the indicated MOI of Ad-SV and Ad-MMP-2. Equal amounts of total protein from conditioned media or cell lysates obtained by lysing cells in a suitable buffer [50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.5 mmol/L henylmethylsulfonylfluoride] were separated on SDS-PAGE and transferred to polyvinylidene difluoride membranes (Bio-Rad). After blocking with 6% nonfat milk and 0.1% Tween 20 in TBS, membranes were incubated with anti-MMP-2 antibody (Chemicon, Temecula, CA), followed by incubation with anti-mouse secondary antibody. Membranes were developed using the ECL system (Amersham Bioscience, Piscataway, NJ). GAPDH antibody was used as a loading control.

Matrigel invasion assay

A2058 cells infected with mock or adenoviral constructs (100 MOI of Ad-SV; 50 and 100 MOI of Ad-MMP-2) were trypsinized and counted. 2×105 cells were placed in matrigel-coated transwell inserts (8-μm pores). Cells were allowed to migrate through the matrigel for 48 hours. Cells were then removed from the upper chamber with a cotton swab. Cells adherent to the outer surface that had invaded through the matrigel were fixed, stained with HEMA, and counted under a light microscope as described previously (21).

Spheroid migration assay

A2058 cells were seeded in 96-well plates coated with 1% agarose in PBS and cultured on a shaker at 90 rpm for 48 hours. After single spheroids formed, cells were infected with mock, Ad-SV (100 MOI), or Ad-MMP-2 (25, 50 and 100 MOI). After 24 hours, spheroids were transferred to 8-well chamber slides and allowed to grow for 48 hours. The results were observed under a confocal scanning laser microscope and the migration distance was measured using Image Pro Discovery software (21).

In vitro angiogenesis assay

Briefly, A2058 melanoma cells were infected with mock, Ad-SV (100 MOI), or Ad-MMP-2 (25, 50 and 100 MOI). After 36 hours, cells were washed with serum-free medium and incubated overnight. The conditioned media was removed and added to a monolayer of 2×104 human microvascular endothelial cells in 96-well plates coated with matrigel. Cells were allowed to grow overnight. Next, cells were washed with PBS and the formation of capillary-like structures was captured using light microscopy. The angiogenic result was measured by counting the relative branch points in each field.

Novel metastatic spine model

Due to the lack of an established, reproducible animal model that allows for easy analysis of tumor progression and resultant paralysis, a novel metastatic spine model was developed using 8 to 10 week-old nude mice (Fig. 1). Animals were placed in either the right or left lateral decubitus position after anesthesia induction via intraperitoneal injection with ketamine 50 mg/kg and xylazine 10 mg/kg. In this position, a natural line forms that originates parallel to the ulna extending out from the olecranon process. This line intersects the spine at approximately the T10 vertebrae. A 1.5 cm incision was made parallel to this line. A #15 scalpel blade was used to dissect through superficial and deep fascia to the depth of the spine. A Hamilton syringe with a blunt tip was then “walked” along the rib from distal to the proximal intersection with the vertebral body. The needle was then translated anteriorly approximately 1-2 mm to avoid the spinal cord and canal. Tactile feedback and moderate pressure assures the syringe tip is within the vertebral body. Animals were then injected with 1×106 melanoma cells/5 μL suspended in serum-free Dulbecco’s modified Eagle medium (DMEM) over 5 min. The skin was closed with glue. Groups were divided into serum-free (control), Ad-SV, or Ad-MMP-2 (1×108 particles/50 μL) treatment groups (5 animals per group) and tail vein injections were performed accordingly on days 5, 9, and 11. Animals were monitored twice daily for the onset of paraplegia. Animals were sacrificed on day 18 or after the onset of paraplegia.

Figure 1
Novel nude mouse model for metastatic spinal melanoma


Spinal cord and columns were removed en bloc and stored in formalin, subsequently decalcified and embedded in paraffin. Hematoxylin and eosin (H&E) was used to visualize cellular morphology, patterns of invasion and mass effect upon the spinal cord. For immunohistochemistry, spinal sections were heated to 65°C for 1 hour, deparaffinized in xylene and rehydrated through graded alcohol. Slides were incubated with 0.1% Triton X-100, blocked with 3% BSA in PBS and incubated with antibodies against HMB45 and MART-1 (Abcam, Cambridge, MA), both of which are ubiquitous antigens found in melanoma. After a rinse in PBS, slides were exposed to secondary anti-mouse antibody for 1 hour at a dilution of 1:200, washed again with PBS, and incubated with 0.05% 3,3’-diaminobenzidine as chromogen. Finally, slides were counterstained with hematoxylin, mounted and observed under a light microscope.


Ad-MMP-2 downregulates MMP-2 protein levels and enzyme activity

To verify that this construct efficiently downregulated the MMP-2 transcript, we infected A2058 human melanoma cells with 12.5, 25, 50, or 100 MOI of Ad-MMP-2. These results were compared to 100 MOI of Ad-SV and the control (non-infected) group. Using conditioned media from the cultured cells, gelatin zymography analysis was performed to determine the activity of the MMP-2 secreted into the media. The 72 kDa bands were progressively less intense with increasing MOI of Ad-MMP-2 demonstrating a dose-dependent MMP-2 inhibition compared to control and Ad-SV-treated cells (Fig. 2A). Equal amounts of protein were obtained from conditioned media of treated and untreated groups for Western blot analysis and demonstrated significantly decreased protein levels of MMP-2 with Ad-MMP-2 constructs compared to Control and Ad-SV-treated cells (Fig. 2B). These results correspond with those found with gelatin zymography.

Figure 2
Adenoviral-mediated transfer of siRNA (Ad-MMP-2) downregulates MMP-2 protein activity and levels

Ad-MMP-2 inhibits melanoma cell invasion

The extracellular matrix (ECM) is the largest obstacle in preventing metastasis of the melanoma cell. MMP-2 has been implicated in the digestion of the basement membrane, which is largely composed of Type IV collagen, also called gelatin. For this reason, we chose to investigate the effect of downregulating MMP-2 via siRNA-mediated methods. The matrigel invasion assay results showed dose-dependent inhibition of tumor cell invasion when treated with Ad-MMP-2 compared to Control and Ad-SV-treated cells (Fig. 3A). After normalization of values as a percentage of the control (100%), those with the highest MOIs of Ad-MMP-2 showed 80-85% inhibition of tumor cell invasion (Fig. 3B).

Figure 3
Downregulation of MMP-2 inhibits cell invasion

Ad-MMP-2 completely inhibits tumor cell migration

Tumor migration is enhanced by MMP-2 as tumor cells degrade the ECM, releasing growth factors necessary for translation through the extracellular milieu. Additionally, there is significant binding to integrins, which serve as anchoring points on the advancing tumor front. Because tumor spheroids mimic tumor migratory characteristics, we formed A2058 spheroids and infected them with 25, 50, or 100 MOI of Ad-MMP-2 and compared these results to the control and Ad-SV groups. Our results show a significant radial migration pattern in the control and Ad-SV groups as compared to complete inhibition at even the lowest doses of Ad-MMP-2 (Fig. 4).

Figure 4
Ad-MMP-2 reduces tumor cell migration

Ad-MMP-2 reduces angiogenesis in vitro

Metastatic tumor cells cannot exist beyond an approximate distance of 1 mm from a direct vascular source, thus requiring angiogenic factors for the continued existence and subsequent growth of tumor cell deposits. Numerous studies have established that MMPs have significant roles in inducing angiogenesis. Here, our results demonstrate that Ad-MMP-2-treated melanoma cells have significantly decreased capillary-like formation in a dose-dependent fashion (Fig. 5A). At the highest MOI of Ad-MMP-2, we observed an almost complete repression of the vascular network (Fig. 5B) compared to control and Ad-SV-treated cells.

Figure 5
In vitro inhibition of angiogenesis

Ad-MMP-2 treatment allows for complete retention of neurological function in vivo

We developed a nude mouse model to study neoplasia, and specifically metastasis of the bony spine. 100% of the control and Ad-SV-treated mice exhibited consistent paraplegia by day 14±2 days with an injection density of 1×106 melanoma cells/5 μL. The paraplegia was abrupt in nature without any preceding gradual loss of function. Notably, the Ad-MMP-2-treated group showed no evidence of paraplegia or diminished neurological function for the duration of the experiment. Furthermore, there was no evidence of morbidity from the surgical procedure, weight loss, or systemic side effects from treatment.

Ad-MMP-2 diminishes tumor size and minimizes mass effect on the spinal cord

After performing immunohistochemistry on the tissue sections, we observed clear visualization of cellular morphology and invasion characteristics of human melanoma. In the control and Ad-SV groups, H&E staining showed sheets of pleomorphic cells with large nucleoli invading from an anterior and anterolateral direction in relation to the spinal cord, mimicking the human pathophysiological state. Furthermore, these cells were found to have proliferated to an extensive degree, which in turn, caused significant compression that often times resulted in distorted spinal cord morphology resembling a crescent (Fig. 6). Melanoma antibody analysis showed that despite proliferation, migration, and invasion, there was no subsequent invasion of the neural elements, including the spinal cord. This indicates that the paraplegia was caused solely by physical compression rather than cellular invasion of the neuraxis.

Figure 6
Tumor growth inhibition in nude mice

In contrast, the Ad-MMP-2-treated group had significant reduction in tumor size (Fig. 6). These results are in accord with the functional results, as all Ad-MMP-2-treated animals retained the ability to walk. Immunohistochemistry did reveal tumor deposits present in the same locations as the control and Ad-SV groups. However, the deposits were diminished in size with no signs of mass effect upon the spinal cord or other neural elements. Thus, while treatment was given intravenously rather than in situ due to the impossibility of that mode of treatment in this model, we were still able to demonstrate in vivo efficacy of systemic adenoviral vector delivery of siRNA.


The current study demonstrates the in vitro and in vivo efficacy of adenovirus-mediated transfer of siRNA against the MMP-2 gene in a novel spinal metastatic melanoma model. The use of adenoviral vectors for gene therapy in cancer is the delivery method of choice due to high infectivity and lack of integration into the host genome, which limits the risk of insertional mutagenesis. Additionally, expression of the adenoviral genome is of short duration without integration, which is all that is necessary for tumor therapy (as compared with chronic genetic disorders that require long-term expression) (22). From this perspective, our results substantiate previous claims as infectivity and expression were high as shown by the in vitro results, lack of mutagenic effects, and retention of neurological function in all treated animals. Furthermore, few studies exist which have used systemic (intravenous) delivery of adenoviral siRNA sequences rather than local intratumoral injection (20,23). Our results demonstrate that it is possible to treat neoplasia to the degree of preventing neurological deficit via the intravenous delivery method, and illustrate the potential of systemic adenoviral delivery of siRNA. This novel and reproducible animal model that we developed to study metastatic spinal melanoma can be applied to practically any tumor and allows for the observation of physical behavior correlating with tumor growth.

RNAi has already been demonstrated as a potent therapy for targeting a wide variety of diseases (24-26). Much of the potential of RNAi is derived from a considerable post-transcriptional silencing effect even at a low concentration; the concentrations required are usually several magnitudes lower than that necessary for antisense oligonucleotide therapy (27,28). Although not integrated into the genome, RNAi activity has been shown to last for more than three weeks via the stability afforded by the RNA interfering silencing complex (RISC) (29). Phase I and II human trials are already underway to determine the safety and effectiveness of local delivery of siRNA for treatment of respiratory synctial virus (RSV) and macular degeneration, and future studies for the treatment of hepatitis, amyotrophic lateral sclerosis (ALS), and HIV are anticipated (18,30).

Cancer cell invasion and metastasis are complex, multi-faceted and multi-step processes, requiring the interaction of cancer cells with the host environment. Within this milieu, there exist many enzymes necessary for the controlled digestion of the basement membrane and extracellular domain. This includes the plasminogen activator system, aspartyl proteinases, cysteine proteinases, serine proteinases, and matrix metalloproteinases. Of these enzymes, general inhibition of MMPs has shown a benefit in melanoma. For example, the synthetic non-specific hydroxamate-type MMP inhibitor batimastat had a 68% inhibition of lung tumor deposits in a B16 murine metastatic melanoma model (31). The support for MMP-2 as a pivotal enzyme in metastasis is strong as this zinc-dependent gelatinase (also known as 72 kDa type IV collagenase) is highly expressed in malignant phenotypes characterized by increasing architectural disorder, atypia, and progression (11,32,33). MMP-2-deficient mice also showed reduced angiogenesis and tumor progression in a metastatic model (34). Furthermore, the data support a correlation between MMP-2 expression and the prognosis of a melanoma patient (35). Because MMP-2 is upregulated in the vertical growth phase of melanoma, and thus, may represent a state of increased invasion and proliferation potential, we hypothesized that specifically targeting MMP-2 would result in significant growth inhibition.

The adenoviral delivery of siRNA against MMP-2 has already been described in the treatment of cancer. For example, in a study involving lung cancer metastasis, siRNA against MMP-2 resulted in decreased invasion, migration, and angiogenesis with a resultant 60% reduction in tumor volume in treated animals (20). Other methods of downregulation have validated MMP-2 as a practical target. Montgomery et al., showed that cDNA transfection with tissue inhibitor of metalloproteinase-2 (TIMP-2) markedly reduced melanoma growth in a cutaneous immunodeficient mouse model although metastasis still ensued (36). The reasons for the observed growth inhibition seen with MMP-2 downregulation are likely multi-factorial. In the initial phase of metastasis, invasion and migration are key steps. In the present study, the matrigel assay results show that MMP-2 downregulation resulted in a greater than 80% inhibition of invasion as compared to the control. This method mimics the basement membrane barrier to invasion, thus illustrating the interaction between tumor cells and the microenvironment. Melanoma cells utilize precise methods of digestion occurring in conjunction with simultaneous adhesion to the stroma. It has been demonstrated that at the invasion front of melanoma, this is characterized by upregulation of MMP-2 only in the aggressive cell lines while MMP-9, TIMP-1 and MT1-MMP were expressed in all cells at the tumor-stromal interface (37). This illustrates the specific actions of MMP-2 not only in the context of its function, but also in its localization of function during metastatic tumor formation.

Post-transcriptional gene control via intravenous injection of adenovirus is classified as non-specific, meaning that theoretically, the DNA sequence is delivered to all cells without tropism towards a specific tissue type other than the known adenoviral affinity for the liver. We propose that some of the growth inhibition observed in vivo may have resulted from the intravenous delivery mechanism, as stromal cells of the bone and peri-spinal region are also theoretically exposed to siRNA. Others have already shown that cells other than the tumor itself can be the major source of MMP-2 in melanoma (38) and tumor growth factors such as the extracellular matrix metalloproteinase inducer (EMMPRIN; CD 147) can induce surrounding fibroblasts to secrete MMP-2 (39,40). In addition, the issue of tumor versus stroma as the source of MMPs is highly variable depending on the tissue studied (37). This observation perhaps strengthens the argument for systemic delivery as one would not need to deliberate the efficacy between intratumoral and intravenous therapy.

Once tumor cells have spread through the vasculature and seeded elsewhere, angiogenesis is a necessary component for subsequent tumor growth as malignant cells with a volume of more than 1-2 mm3 exceed the maximum diffusability of required nutrients necessary to sustain tumor growth (41). Thus, in the absence of neovascularization, solid tumor deposits could not exceed a certain, small dimension. Our results support this mechanism as the immunohistochemical data show the presence of tumor in the treated animals but failure of sustained growth. This may be due to the downregulation of MMP-2-induced angiogenesis. This assertion is corroborated by our in vitro data, which demonstrate the vascular tubular network was repressed to 30% of control levels. Indeed, others have shown this same effect. Fang et al., demonstrated via gel electrophoresis that the switch to the angiogenic phenotype correlated with an increase in MMP-2 in a rat chondrosarcoma model. Specific inhibition of MMP-2 resulted in decreased angiogenic and proteolytic activity of tumor nodules and suppressed in vivo tumor growth by 70% (42). The vitronectin-binding integrin αvβ3, which is highly expressed in melanoma metastases, binds active MMP-2 on the cell surface of endothelial cells and apparently promotes vascular proliferation. Active blocking of this interaction results in reduced tumor vascularity and size (43). Radiation-induced angiogenesis was also found to be partially mediated by MMP-2 in B16 melanoma cells. This effect was abrogated by the MMP inhibitor metastat (44).

Our rationale for developing a novel model was the lack of established protocols in studying neoplasia and the spine. A previous model utilizes left ventricular intracardiac injection in a murine metastatic B16 melanoma model (45). While the yield was high with tumor nodules forming in 100 percent of animals, there was widespread metastatic involvement from the onset. With this high tumor load, the animal may deteriorate physically which may limit survival, thus affecting final analysis of the treatment results. Furthermore, this model may significantly alter or lower the volume of distribution in systemically administered adenovirus as other studies have found clustering of siRNA in and around the tumor neovasculature (22). More recent animal models describe anatomically correct but technically difficult procedures in rabbits, requiring drilling and surgical expertise (46). In contrast, our model requires little training and materials, and isolates metastatic disease to the spine with physically observable effects of tumor progression, namely paraplegia. Furthermore, we sought to recreate the pathophysiological state of spinal cord compression from metastatic tumor involvement of the vertebral body. In humans, the vast majority of tumor deposits occur in the vertebral body due to the presence of large amounts of hematopoietic marrow (47). Resultant growth and local spread of the tumor results in spinal cord compression from an anterior and lateral direction (48). As evidenced by the immunohistochemistry results, we were able to successfully mimic this scenario. Our results also indicate a correlation between paraplegia and the amount of tumor burden. Those with intact function had little tumor deposit present within the vertebral body while those with paraplegia had widespread tumor involvement from the anterior and lateral directions with direct compressive forces resulting in significant distortion of the spinal cord.

The present study validates systemic adenoviral siRNA delivery and the targeting of MMP-2 in metastatic melanoma. We have demonstrated significantly diminished tumor cell invasion, migration, and angiogenesis. In vivo, these results correlated with retention of neurological function in a novel metastatic spinal model. While other metastatic models to date rely upon either intracardiac injection or technically more involved procedures, this model relies upon simple anatomical concepts with reproducible results and confirmed immunohistochemical mimicry of the human pathophysiological state. The fact that tumor was still observed within the vertebrae of treated animals imply that the RNAi approach, while valid, may require a multimodal strategy aimed at all the specific steps involved in metastasis. With foreseeable improvements in siRNA delivery and specificity, proteases such as MMP-2 may become attractive targets in the clinical therapy of cancer and metastatic disease.


The authors thank Shellee Abraham for preparing the manuscript and Diana Meister and Sushma Jasti for manuscript review. We also thank Noorjehan Ali for technical assistance.

This research was supported by National Cancer Institute Grant CA 75557, CA 92393, CA 95058, CA 116708, N.I.N.D.S. NS47699 and NS057529, and Caterpillar, Inc., OSF Saint Francis, Inc., Peoria, IL (to J.S.R.).

Abbreviations used

Matrix metalloproteinase
Adenoviral construct for MMP-2 siRNA
Adenoviral construct for Scrambled sequence control
Tissue Inhibitor of Metalloproteinase
small interfering RNA
extracellular matrix

Reference List

1. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol. 2002;29:518–524. [PubMed]
2. Gerszten PC, Burton SA, Quinn AE, Agarwala SS, Kirkwood JM. Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg. 2005;83:213–221. [PubMed]
3. Gokaslan ZL, Aladag MA, Ellerhorst JA. Melanoma metastatic to the spine: a review of 133 cases. Melanoma Res. 2000;10:78–80. [PubMed]
4. Spiegel DA, Sampson JH, Richardson WJ, Friedman AH, Rossitch E, Hardaker WT, Jr, Seigler HF. Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients. Spine. 1995;20:2141–2146. [PubMed]
5. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366:643–648. [PubMed]
6. Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys. 1986;12:867–872. [PubMed]
7. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260–1270. [PubMed]
8. Lakka SS, Rao JS. Role and regulation of matrix metalloproteases in brain tumors. In: Conant K, Gottschall PE, editors. Matrix Metalloproteinases in the Central Nervous System. London: Imperial College Press; 2005. pp. 263–278.
9. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J. 1994;7:2062–2072. [PubMed]
10. Hofmann UB, Westphal JR, van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol. 2000;115:337–344. [PubMed]
11. Hofmann UB, Westphal JR, Waas ET, Zendman AJ, Cornelissen IM, Ruiter DJ, van Muijen GN. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer. 1999;81:774–782. [PMC free article] [PubMed]
12. Capon F, Emonard H, Hornebeck W, Maquart FX, Bernard P. Expression and activation of pro-gelatinase A by human melanoma cell lines with different tumorigenic potential. Clin Exp Metastasis. 1999;17:463–469. [PubMed]
13. Ikeda T, Murakami K, Sakukaw R, Hayakawa Y, Saiki I. Characterization of a liver metastatic variant of murine K1735M2 melanoma cells. In Vivo. 2000;14:519–527. [PubMed]
14. Montgomery AM, De Clerck YA, Langley KE, Reisfeld RA, Mueller BM. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res. 1993;53:693–700. [PubMed]
15. Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen WT. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci USA. 1997;94:7959–7964. [PubMed]
16. Redondo P, Lloret P, Idoate M, Inoges S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol. 2005;30:541–545. [PubMed]
17. Wollina U, Hipler UC, Knoll B, Graefe T, Kaatz M, Kirsch K. Serum matrix metalloproteinase-2 in patients with malignant melanoma. J Cancer Res Clin Oncol. 2001;127:631–635. [PubMed]
18. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173–184. [PubMed]
19. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002;2:243–247. [PubMed]
20. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, Lakka SS. Adenovirus-mediated siRNA against MMP-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther. 2006;5:2289–2299. [PubMed]
21. Lakka SS, Rajan M, Gondi CS, Yanamandra N, Chandrasekar N, Jasti SL, Adachi Y, Siddique K, Gujrati M, Olivero W, Dinh DH, Kouraklis G, Kyritsis AP, Rao JS. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene. 2002;21:8011–8019. [PubMed]
22. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. Delivery of RNA interference. Cell Cycle. 2006;5:2103–2109. [PubMed]
23. Schmitz V, Vilanueva H, Raskopf E, Hilbert T, Barajas M, Dzienisowicz C, Gorschluter M, Strehl J, Rabe C, Sauerbruch T, Prieto J, Caselmann WH, Qian C. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice. Gene Ther. 2006;13:1198–1205. [PubMed]
24. Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW, Whang EE. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg. 2004;240:667–674. [PubMed]
25. Filleur S, Courtin A, it-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, Clezardin P, Cabon F. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003;63:3919–3922. [PubMed]
26. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9:347–351. [PubMed]
27. Coma S, Noe V, Lavarino C, Adan J, Rivas M, Lopez-Matas M, Pagan R, Mitjans F, Vilaro S, Piulats J, Ciudad CJ. Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides. 2004;14:100–113. [PubMed]
28. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–498. [PubMed]
29. Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430:161–164. [PubMed]
30. Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, Hellermann G, Behera S, Singam R, Lockey RF, Mohapatra SS. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med. 2005;11:56–62. [PubMed]
31. Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, Giavazzi R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994;58:460–464. [PubMed]
32. Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein CE, Krieg T, Mauch C. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem. 1999;274:21056–21062. [PubMed]
33. Vaisanen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol. 1996;180:283–289. [PubMed]
34. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998;58:1048–1051. [PubMed]
35. Vaisanen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol. 1998;186:51–58. [PubMed]
36. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res. 1994;54:5467–5473. [PubMed]
37. Hofmann UB, Eggert AA, Blass K, Brocker EB, Becker JC. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res. 2003;63:8221–8225. [PubMed]
38. Hofmann UB, Eggert AA, Blass K, Brocker EB, Becker JC. Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma. Arch Dermatol Res. 2005;297:154–160. [PubMed]
39. Li R, Huang L, Guo H, Toole BP. Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J Cell Physiol. 2001;186:371–379. [PubMed]
40. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001;61:2276–2281. [PubMed]
41. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4–6. [PubMed]
42. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA. 2000;97:3884–3889. [PubMed]
43. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA. 2001;98:119–124. [PubMed]
44. Kaliski A, Maggiorella L, Cengel KA, Mathe D, Rouffiac V, Opolon P, Lassau N, Bourhis J, Deutsch E. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther. 2005;4:1717–1728. [PubMed]
45. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988;48:6876–6881. [PubMed]
46. Amundson E, Pradilla G, Brastianos P, Bagley C, Riley LH, III, Garonzik IM, McCarthy E, Wolinsky JP, Gokaslan ZL. A novel intravertebral tumor model in rabbits. Neurosurgery. 2005;57:341–346. [PubMed]
47. Thrall JH, Ellis BI. Skeletal metastases. Radiol Clin North Am. 1987;25:1155–1170. [PubMed]
48. Fornasier VL, Horne JG. Metastases to the vertebral column. Cancer. 1975;36:590–594. [PubMed]